Compounds > pentarane b
Page last updated: 2024-12-07

pentarane b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pentarane B: exhibits no affinity for the chick progesterone receptor but interacted with calf uterine progesterone receptor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID124372
MeSH IDM0226344

Synonyms (10)

Synonym
16,24-cyclo-21-norchol-4-en-3-one, 17-acetyl-6-methyl-, (6alpha,16beta,17alpha)-
6alpha-methyl,16alpha,17alpha-cyclohexanoprogesterone
pentarane b
58212-84-3
(4ar,4bs,6as,6bs,10ar,11as,11br,13s)-6b-acetyl-4a,6a,13-trimethyl-3,4,4a,4b,5,6,6a,6b,7,8,9,10,10a,11,11a,11b,12,13-octadecahydro-2h-indeno[2,1-a]phenanthren-2-one
n3uwj2k7nf ,
mecigestone
unii-n3uwj2k7nf
DTXSID30973778
(6alpha,16beta,17alpha)-17-acetyl-6-methyl-16,24-cyclo-21-norchol-4-en-3-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (60.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.40 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
dihydrotestosterone
Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.		21017beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
pentarane a
pentarane A: exhibits no affinity for the chick progesterone receptor but interacts with calf uterine progesterone receptor; structure given in first source		2.6830
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		02.0110
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0110
Cancer of the Uterus
[description not available]		01.9810
Cancer of Endometrium
[description not available]		01.9810
Uterine Neoplasms
Tumors or cancer of the UTERUS.		01.9810
Endometrial Neoplasms
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.		01.9810